Jubira F 5 Tablet is a combination lipid-lowering medication containing Fenofibrate 160 mg and Rosuvastatin 5 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing total cholesterol and LDL-C levels. The combination therapy is particularly beneficial for patients with persistent lipid abnormalities despite monotherapy, addressing multiple lipid parameters simultaneously to reduce cardiovascular risk. Jubira F 5 is prescribed as an adjunct to diet and lifestyle modifications in adults with hypercholesterolemia or mixed dyslipidemia. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver function tests, renal function, and lipid profiles is recommended. Potential adverse effects include myopathy, elevated liver enzymes, and gastrointestinal disturbances. This combination should be used under medical supervision to optimize lipid control and minimize adverse effects.